文献速递血液净化与透析

维持性透析患者接种第三剂BNT162b2疫苗后的SARS-CoV-2抗体反应

SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
PubMed 文献 · Am J Kidney Dis · 2021-09-08

该病例系列纳入69例法国透析患者(38例血透、31例腹透),评估第三剂BNT162b2疫苗后抗S1抗体水平。第二剂后中位抗体284 AU/mL,第三剂后升至7,554 AU/mL;初始无应答者3例中1例产生抗体,12例弱应答者抗体均升高。第三剂耐受性与第二剂相似。

要点

  • 第三剂BNT162b2可显著提高透析患者抗S1抗体水平。
  • 第二剂后弱应答者第三剂后抗体均升高,部分无应答者产生抗体。
  • 第三剂不良反应未比第二剂更常见或更严重。

核心结论

  • 第三剂BNT162b2疫苗大幅提高维持性透析患者的抗体水平,且耐受性与第二剂相似。

研究设计与样本

  • 病例系列,纳入单中心69例法国维持性透析患者(38例血透、31例腹透),均接种3剂BNT162b2疫苗。

主要发现

  • 第二剂后中位抗S1抗体水平为284(IQR 83-1190)AU/mL,第三剂后至少3周为7,554(IQR 2,268-11,736)AU/mL。
  • 第二剂后3例无应答(抗S1抗体<0.8 AU/mL),12例弱应答(0.8-50 AU/mL);第三剂后1例无应答者产生抗体,12例弱应答者抗体水平均升高。
  • 第三剂后抗体升高幅度更大的患者,第二剂后抗体水平更低,且第二至第三剂间隔更长。
  • 第三剂后不良事件似乎未比第二剂更常见或更严重。

临床怎么用

  • 对维持性透析患者,第三剂BNT162b2疫苗可考虑用于提升抗体应答。

局限性

  • 观察性研究,样本量小。
  • 抗体水平与临床结局的关系尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Recent studies showed that antibody titers after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the dialysis population are diminished as compared with the general population, suggesting the possible value of a third booster dose. We characterized the humoral response after 3 doses of the BNT162b2 vaccine in patients treated with either maintenance hemodialysis (HD) or peritoneal dialysis (PD). STUDY DESIGN: Case series. SETTING & PARTICIPANTS: 69 French patients (38 HD and 31 PD) treated at a single center who received 3 doses of the BNT162b2 vaccine. FINDINGS: Humoral response was evaluated using plasma levels of anti-SARS-CoV-2 spike protein S1 immunoglobulin measured after the second dose and at least 3 weeks after the third dose of the BNT162b2 vaccine. Patients (median age 68 years [interquartile range (IQR), 53-76 years], 65% men) had a median anti-S1 antibody level of 284 [IQR, 83-1190] AU/mL after the second dose, and 7,554 [IQR, 2,268-11,736] AU/mL after the third dose. Three patients were nonresponders (anti-S1 antibody level < 0.8 AU/mL), and 12 were weak responders (anti-S1 antibody level 0.8-50 AU/mL) after the second vaccine dose. After the third dose, 1 of the 3 initial nonresponders produced anti-spike antibody, and all the 12 initial weak responders increased their antibody levels. Patients with a greater increase in anti-S1 antibody levels after a third dose had lower antibody levels after the second dose, and a longer time interval between the second and the third dose. Adverse events did not seem to be more common or severe after a third vaccine dose. LIMITATIONS: Observational study, small sample size. Relationship between antibody levels and clinical outcomes is not well understood. CONCLUSIONS: A third dose of the BNT162b2 vaccine substantially increased antibody levels in patients receiving maintenance dialysis and appeared to be as well tolerated as a second dose.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Bensouna I, Caudwell V, Kubab S, et al. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis. Am J Kidney Dis. 2021. PMID: 34508833. doi:10.1053/j.ajkd.2021.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。